Background. In spite of the beneficial effect of iron supplementation in iron-deficient pregnant women, iron supplementation may not be needed for women who are iron replete or not anemic. Moreover, the theoretical possibility of adverse effects, such as oxidative damage, from administration of iron supplements during pregnancy has been raised.
Introduction
Iron-deficiency anemia is the most common nutritional problem in both developed and developing countries. During the past few years, a relation between anemia early in pregnancy and an increased risk of preterm delivery has been suggested. Likewise, the relation of adverse pregnancy outcomes with high hemoglobin and increased iron stores has been documented [1, 2] . At the present time in Iran, iron supplementation is performed for both healthy and iron-deficient pregnant women.
In spite of the beneficial effect of iron supplementation in iron-deficient pregnant women, iron supplementation may not be needed for women who are iron replete or not anemic. Moreover, the theoretical possibility of adverse effects, such as oxidative damage, from administration of iron supplements during pregnancy has been raised [3] . Also, elevated hemoglobin, hematocrit, and ferritin are associated with increased risks of fetal growth restriction, preterm delivery, preeclampsia, and gestational diabetes mellitus [2] [3] [4] . Intake of iron tablets has resulted in gastrointestinal side effects [5] . Moderately elevated iron stores also increase the risk of type 2 diabetes [6] . Women with high ferritin levels during the third trimester of pregnancy have a greatly increased risk of preterm and very preterm delivery [7] .
Anemia in early pregnancy may result in preterm delivery and low birthweight, whereas anemia in the third trimester is not usually associated with an increased risk of adverse pregnancy outcomes [2] . During the second and third trimesters, physiologic anemia may occur due to expanded maternal plasma volume. It is difficult to distinguish physiologic anemia from irondeficiency anemia [2] .
Iron supplementation may improve pregnancy outcomes when the mother is iron depleted, is iron deficient, or has iron-deficiency anemia. It is possible that prophylactic supplementation increases the risk of adverse effects when the mother is not anemic. The risks and benefits of prophylactic iron supplementation in pregnant women who are not iron deficient remain controversial and should be examined further [2, 8] . In consideration of the scarcity of data on the effect of iron supplementation in nonanemic pregnant women, the aim of this study was to determine the effects of prophylactic iron supplementation on iron status and birth outcomes in pregnant women who are not anemic.
Subjects and methods

Study population
The study population consisted of 148 pregnant women who visited the gynecology center in Khorramabad City, Lorestan Province, in western Iran. The inclusion criteria were nonanemic pregnant women with gestational age < 20 weeks, primigravidae, age between 20 and 35 years, body mass index (BMI) > 25 and < 30, hemoglobin > 110 g/L, and serum ferritin > 20 μg/L. The exclusion criteria were diabetes mellitus, coronary heart disease, thalassemia, renal disease, respiratory disease, use of supplementary multivitamins or minerals, drug use, and being on a special diet.
Design
The purpose and design of this triple-blind, randomized clinical trial were explained to each eligible participant in written form and orally by the gynecologist in the informed consent procedure, with emphasis on the requirement for random allocation to receive standard iron supplementation or placebo. The study protocol was approved by the Ethics Committee of Lorestan University of Medical Sciences (IRCT ID: IRCT138706141196N1).
Initial venous blood samples (5 mL) were drawn, and eligible women (hemoglobin > 110 g/L, serum ferritin > 20 μg/L) were randomly allocated to receive one tablet orally per day containing either 60 mg of iron (this dose is given routinely to pregnant Iranian women at healthcare centers) as ferrous sulfate (iron group, n = 70) or placebo (n = 78) until delivery. The tablets were manufactured by Rose Daru, Tehran, and were coated by Exir, Lorestan. Women who were anemic or iron deficient were referred for medical evaluation and treated.
The blood samples were sent immediately by a pneumatic tube carrier transport system to the laboratory on an upper floor of the same building. The samples were immediately removed from the carrier and divided in two parts; one part was refrigerated at 4° C until whole blood analysis was performed, and the another was used for serum separation. The samples were stored at -70°C until analysis.
Hemoglobin concentration was measured with a Coulter electronic counter, model K-800. Serum ferritin was measured by a radioimmunoassay with a Gamacounter, model 1001.
The placebos were formulated to be indistinguishable from the tablets containing iron. At the first visit, each subject was given a bottle containing a 30-day supply of either placebo or iron tablets. Additional tablets were dispensed at subsequent monthly clinic visits until the time of delivery. A label on each bottle included a number linking the bottle to the type of tablet. The physician, laboratory analysts, and subjects were not aware of the type of tablet.
Hemoglobin and serum ferritin were measured in the blood samples at the initial visit, week 28 of gestation, and delivery. Birthweight and birth length were measured to the nearest 0.1 kg and 0.1 cm, respectively. The duration of pregnancy (gestation period) was calculated as the number of weeks from the reported last menstrual period to the delivery date.
Statistical analysis
The questionnaires were coded, and the data were entered into SPSS, version 15.0. Independent t-tests were used to compare the baseline quantitative characteristics. Analysis of covariance (ANCOVA) was used to compare the main quantitative outcomes with adjustment for the confounder baseline variables. Repeated measures were used to compare the main quantitative outcomes several times throughout the study. Differences were considered significant if the p value was less than .05. Table 1 gives the baseline characteristics of the subjects. The groups did not differ significantly in weight, height, BMI, or gestational age, but the difference in age was significant. Table 2 shows body iron indices and the prevalence of iron deficiency and iron-deficiency anemia in the iron and placebo groups during the study period. There were no significant differences between the iron and placebo groups in iron indices throughout the study (baseline, 28 weeks of gestation, and delivery) except for the rate of iron deficiency. Table 3 shows birth outcomes for women in the iron and placebo groups. The prevalence rates of low birthweight and preterm delivery were not significantly different between the groups.
Results
Discussion
Our study showed that daily iron supplements given to initially iron-replete, nonanemic pregnant women did not lead to significant changes in hemoglobin or ferritin concentrations. Adjustment of the results for age suggested that, compared with placebo, iron supplementation led to a significantly lower proportion of women with low iron stores at 28 weeks of gestation and at delivery. However, the hemoglobin concentration decreased in both the iron and the placebo groups during gestation. In our study, iron supplementation decreased the rates of low birthweight and preterm delivery. It is possible that iron supplements may be preferentially transferred to the placenta and fetus and thus contribute to higher birthweight rather than to higher maternal iron stores. However, the real mechanism or mechanisms are unknown. Cogswell et al. [3] showed that iron supplementation from enrollment (before 20 weeks of gestation) to 28 weeks of gestation did not significantly affect the overall prevalence of anemia in nonanemic pregnant women. In their study, the hemoglobin concentration significantly decreased from conception to the third trimester (from 129 ± 9 to 117 ± 9 g/L in the iron group and from 127 ± 10 to 116 ± 10 g/L in the placebo group) [3] . In our study, the prevalence of iron deficiency at delivery was significantly higher in the placebo group than in the iron group. Mohamed [9] showed that compared with placebo, iron supplements given to pregnant women led to a significantly lower prevalence of iron-deficiency anemia. Risonar et al. [10] showed that the redesigned iron supplementation delivery system for pregnant women in Negros Occidental, Philippines, was effective in improving the hemoglobin concentration and health-related behavior of pregnant women. Palma et al. [11] showed that giving 80 mg of ferrous sulfate was associated with a decreased risk of low birthweight in nonanemic women. Zeng et al. [4] reported that supplementation with multiple micronutrients was associated with modestly increased birthweight compared with supplementation with folic acid, but despite this weight gain, there was no significant reduction in early neonatal mortality [4] .
In spite of these studies, other studies failed to show any effect of routine iron supplementation on the prevalence of anemia in pregnant women [12, 13] . Siega-Riz et al. [8] showed that daily prenatal supplementation with 30 mg of iron in nonanemic women with sufficient iron stores had no significant effect on iron status. However, serum ferritin decreased at the beginning of the third trimester in both the supplemented and the placebo groups.
We did not find any differences between the two treatment groups in birthweight, birth length, or length of the gestation period. These findings are different from those of Cogswell et al. [3] , perhaps due to the small sample size in our study.
In the study of Siega-Riz et al. [8] , contrary to our results, mean birthweight was higher and the incidence of preterm delivery was lower in the iron-supplemented group than in the control group. Other studies similar a. Plus-minus values are means ± SD. b. Iron deficiency was defined as serum ferritin < 12 μg/L. The difference between groups was significant at gestational week 28 and delivery (p < .05). c. Iron-deficiency anemia was defined as hemoglobin concentration < 110 g/L and serum ferritin < 12 μg/L. The difference between groups was significant at gestational week 28 (p < .05). to ours did not find a significant difference in pregnancy outcome between the iron-supplemented group and the placebo group [14, 15] . A comprehensive review concluded that virtually all published intervention studies had major flaws that prevent definitive conclusions to be drawn about the effect of iron supplementation on pregnancy outcome [16] . Iron supplementation in pregnant women with iron deficiency is useful, but prophylactic iron supplementation in nonanemic pregnant women who have sufficient iron stores may be associated with risk to pregnancy outcomes [2] .We found one case of pregnancy-induced hypertension and three cases of abortion in the iron group and one case of abortion in the placebo group (data not shown). The differences between the groups were not significant, perhaps due to the small sample size. Murphy et al. [17] stated that hemoglobin concentrations above 133 g/L increase the risk of adverse outcomes in pregnancy. High hemoglobin concentrations may also increase the risk of hypertension during pregnancy. Furthermore, Zhou et al. [18] showed that hemoglobin levels above 130 g/L increase the risks of preterm delivery and low birthweight.
Tiwari et al. [19] found that the undesirable side effects such as lipid peroxidation of iron supplementation were greater in the mildly anemic than in the moderately and severely anemic group, whereas nausea, vomiting, and systemic reactions were negligible in all treated iron-deficient anemic women. They suggested that blind iron supplementation should be avoided and supplementation should be provided on a need basis. Other studies showed that lipid peroxidation results from daily iron supplementation [20] and elevated ferritin in pregnancy induces hypertension and eclampsia [21] .
We also found a significant relationship between iron deficiency at delivery and initial serum ferritin levels in the lowest quartile. Thus, it would be preferable to simply target the number of pregnant women with low serum ferritin at the beginning (less than 20 weeks of gestation) for supplementation. This would avoid giving unneeded iron to the large majority of women who are iron replete. Further studies with larger sample sizes are needed in this area.
In conclusion, iron supplementation during pregnancy in nonanemic women with low serum ferritin may have benefits beyond the prevention of irondeficiency anemia by decreasing the incidence of low birth weight and preterm delivery. However, supplements should be used with caution because of possible side effects.
